Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis

Autoimmunity

Volumn 45, Issue 4, 2012, Pages 298-303

  Gnanapavan, Sharmilee ^a,b   Grant, Donna ^a   Pryce, Gareth ^b   Jackson, Sam ^b   Baker, David ^b   Giovannoni, Gavin ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

axonal loss; ELISA; G93A SOD1; inflammation; scaffolding protein

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NEUROFILAMENT PROTEINS; SUPEROXIDE DISMUTASE;

EID: 84859809115     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.654865     Document Type: Article

References (30)

1. Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol 2005;165:4-52.
2. Jackson SJ, Lee J, Nikodemova M, Fabry Z, Duncan ID. Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol 2009;68: 616-625.
3. Jackson SJ, Diemel LT, Pryce G, Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005;233:21-25. (Pubitemid 40804812)
4. BakerD, O'Neill JK, Geschmeissner SE, Wilcox CE, Butter C, Turk JL. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 28: 261-270.
5. Hampton DW, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008;201-202:200-211.
6. Eikelenboom MJ, et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003;60:219-223. (Pubitemid 36152012)
7. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005;11:532-536. (Pubitemid 41387697)
8. Petzold A, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005;76:206-211. (Pubitemid 40143709)
9. Gunnarsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-89.
10. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285. (Pubitemid 28065253)
11. De Stefano N, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-1571.
12. Weiner HL. A shift from adaptive to innate immunity: A potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255 Suppl 1:3-11. (Pubitemid 351341867)
13. Carden MJ, Schlaepfer WW, Lee VM. The structure, biochemical properties, and immunogenicity of neurofilament peripheral regions are determined by phosphorylation state. J Biol Chem 1985;260:9805-9817. (Pubitemid 15013039)
14. Pant HC. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem J 1988;256:665-668. (Pubitemid 19006034)
15. Gurney ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 1997;244 Suppl 2: S15-S20. (Pubitemid 27208006)
16. Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D. Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH Mouse. Mult Scler Rel Dis 2011;1:29-38.
17. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190. (Pubitemid 37281201)
18. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002;58:1372-1381. (Pubitemid 34507164)
19. Kuhle J, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76:1206-1213.
20. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, Borchelt D, Shaw G. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009;111:1182-1191.
21. Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML. A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration. Am J Pathol 2002;161: 1577-1586. (Pubitemid 35265518)
22. Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler 2011;17: 939-948.
23. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011;117:528-537.
24. Krishnamoorthy G, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009;15:626-632.
25. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007;116:100-107. (Pubitemid 47174178)
26. Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003;5:157-164.
27. Garcia-Martin E, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler 2011;17:830-837.
28. Talman LS, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010;67:749-760.
29. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129:595-605. (Pubitemid 43278222)
30. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-1929.